1.88
-0.045(-2.34%)
Currency In USD
| Previous Close | 1.92 |
| Open | 1.92 |
| Day High | 1.93 |
| Day Low | 1.84 |
| 52-Week High | 5.17 |
| 52-Week Low | 1.05 |
| Volume | 967,142 |
| Average Volume | 1.03M |
| Market Cap | 203.12M |
| PE | -1.19 |
| EPS | -1.57 |
| Moving Average 50 Days | 1.8 |
| Moving Average 200 Days | 1.83 |
| Change | -0.05 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) since IPO date, it would be worth $170.45 as of September 30, 2025 at a share price of $1.875. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $729.57 as of September 30, 2025 at a share price of $1.875.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
GlobeNewswire Inc.
6 hours ago
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company w
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
GlobeNewswire Inc.
Sep 09, 2025 11:00 AM GMT
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company wi